Regulation and Essentiality of the StAR-related Lipid Transfer (START) Domain-containing Phospholipid Transfer Protein PFA0210c in Malaria Parasites. by Hill, Ross J et al.
Hill, RJ; Ringel, A; Knuepfer, E; Moon, RW; Blackman, MJ; van
Ooij, C (2016) Regulation and essentiality of the START-domain-
containing phospholipid transfer protein PFA0210c in malaria para-
sites. The Journal of biological chemistry, 291 (46). pp. 24280-24292.
ISSN 0021-9258 DOI: https://doi.org/10.1074/jbc.M116.740506
Downloaded from: http://researchonline.lshtm.ac.uk/2965064/
DOI: 10.1074/jbc.M116.740506
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Regulation and Essentiality of the StAR-related Lipid Transfer
(START) Domain-containing Phospholipid Transfer Protein
PFA0210c in Malaria Parasites*
Received for publication,May 26, 2016, and in revised form, September 23, 2016 Published, JBC Papers in Press,October 2, 2016, DOI 10.1074/jbc.M116.740506
Ross J. Hill‡1, Alessa Ringel‡2, Ellen Knuepfer‡, Robert W. Moon§, Michael J. Blackman‡¶, and Christiaan van Ooij‡3
From the ‡The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7 1AA and the Departments of
§Infection and Immunity and ¶PathogenMolecular Biology, London School of Hygiene & Tropical Medicine,
London WC1E 7HT, United Kingdom
Edited by George Carman
StAR-related lipid transfer (START) domains are phospho-
lipid- or sterol-binding modules that are present in many pro-
teins. START domain-containing proteins (START proteins)
play important functions in eukaryotic cells, including the redis-
tribution of phospholipids to subcellular compartments and
delivering sterols to the mitochondrion for steroid synthesis.
How the activity of the START domain is regulated remains
unknown for most of these proteins. The Plasmodium falcipa-
rum START protein PFA0210c (PF3D7_0104200) is a broad-
spectrum phospholipid transfer protein that is conserved in all
sequencedPlasmodium species and ismost closely related to the
mammalian STARTproteins STARD2 and STARD7. PFA0210c
is unusual in that it contains a signal sequence and a PEXEL
export motif that together mediate transfer of the protein from
the parasite to the host erythrocyte. The protein also contains a
C-terminal extension, which is very uncommon among mam-
malian STARTproteins.Whereas the biochemical properties of
PFA0210c have been characterized, the function of the protein
remains unknown. Here, we provide evidence that the unusual
C-terminal extension negatively regulates phospholipid trans-
fer activity. Furthermore, we use the genetically tractable Plas-
modium knowlesi model and recently developed genetic tech-
nology in P. falciparum to show that the protein is essential for
growth of the parasite during the clinically relevant asexual
blood stage life cycle. Finally, we show that the regulation of
phospholipid transfer by PFA0210c is required in vivo, and we
identify a potential second regulatory domain. These findings
provide insight into a novel mechanism of regulation of phos-
pholipid transfer in vivo and may have important implications
for the interaction of the malaria parasite with its host cell.
Phospholipid transfer proteins play important roles in the
trafficking of phospholipids within eukaryotic cells (1). One
subset of phospholipid transfer proteins is represented by a
group of proteins containing a StAR-related (START)4 lipid-
transfer domain, whichmediates the binding to lipids or sterols
and can promote their transfer between membranes. Although
sequence similarity between different START domains can be
very low, all are characterized by a specific fold consisting of
four -helices and a nine-stranded twisted antiparallel -sheet
that together form a cavity in which a hydrophobic phospho-
lipid or sterol is held (2, 3). The human genome encodes 15
different START domain-containing proteins (START pro-
teins) that can be categorized into five different groups based on
the bound ligand specificity and the presence of additional
functional domains (Table 1) (4–7). The roles of the different
START proteins are in most cases not well understood,
although mutations in genes encoding START proteins have
been linked with various diseases (5, 8). It is clear from genetic
experiments in mice that at least two of the murine START
proteins, STARD11 and STARD12, are essential (9, 10). The
best characterized human START proteins are STARD2,
STARD7, and STARD10, which all transfer phosphatidylcho-
line (and additionally phosphatidylethanolamine in the case of
STARD10) (11–13). Although their exact functions are unclear,
the proteins appear to have a role in the transfer of phospholip-
ids from the endoplasmic reticulum to mitochondria and pos-
sibly the plasma membrane (14, 15). What is also not under-
stood is whether and how the transfer of phospholipids by these
proteins is regulated. Some of the START proteins consist of
little more than the START domain itself, whereas others con-
tain additional domains, such as thioesterase or Rho-GAP
domains (Table 1). Some START proteins, including STARD2
and STARD12, have been shown to interact with other proteins
(16, 17), which may provide a mechanism of regulating phos-
pholipid transfer activity, or conversely, to allow the START
protein to regulate the interacting protein. In the case of
STARD10, phosphorylation of a residue in a C-terminal exten-
sion has been shown to regulate transfer activity (18).
Most members of the genus Plasmodium, which are the obli-
gate intracellular parasites that causemalaria, encode four START
proteins (19). These include a putative orthologue of STARD2
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(phosphatidylcholine transfer protein; PF3D7_1351000) and an
uncharacterized protein (PF3D7_0911100) with a putative
cyclin-dependent serine/threonine kinase domain that also
contains a START domain at its C terminus. The third START
protein (PF3D7_1463500) displays similarity to StarD3
(MLN64), a cholesterol transfer protein (20). Interestingly, in
rodent malaria parasites this protein forms part of the large
Fam A family, whereas in non-rodent malaria parasites, only
one family member is present (21–23). The best character-
ized START protein in Plasmodium spp. is the exported
broad specificity phospholipid transfer protein PFA0210c
(PF3D7_0104200). PSI-BLAST analysis shows that PFA0210c
is most closely related to STARD7, whereas structure predic-
tion reveals that the highest similarity is to human phosphati-
dylcholine transfer protein STARD2 (24).
Phospholipid transfer proteins in Plasmodium are of partic-
ular interest as one of the most striking changes induced by the
parasite in the host erythrocyte, the site of replication of the
parasite during the clinical stage of the disease, is the formation
of a large exomembrane system (25). This consists of several
different, most likely unconnected, membranous compart-
ments that have various functions within the cell. One of these
membranous compartments is the parasitophorous vacuole
membrane that surrounds the parasite during the entire intra-
erythrocytic life cycle and that separates the parasite from the
erythrocyte cytosol. Another group of membranous compart-
ments is the Maurer’s clefts, small vesicles that are important
for the transfer of parasite proteins to the surface of the infected
cell (26, 27). As mature erythrocytes are devoid of internal
membranes and lack the capacity to produce membranes (28),
these newly formed membranes, which are all outside of and
unconnected to the parasite, must be produced by the parasite.
How the parasite transfers phospholipids across the aqueous
environment of the parasitophorous vacuole lumen to the para-
sitophorous membrane and the Maurer’s clefts is unknown. It
has been suggested that PFA0210c may play a part in this pro-
cess (24). In support of this, a unique feature of PFA0210c
among the Plasmodium falciparum START proteins is the
presence of a signal sequence, which mediates the secretion of
the protein from the parasite into the parasitophorous vacuole,
as well as a PEXEL export signal, which directs export beyond
the parasitophorous vacuole membrane into the erythrocyte
cytosol (Fig. 1A). Previous studies have indicated that
PFA0210c can be exported from the parasite to the erythrocyte
cytosol (29), although at least a fraction remains in the parasi-
tophorous vacuole (24). The presence of the protein at these
locations indicates that it may function to transfer phospholip-
ids between the parasite and parts of the exomembrane system.
Here, we show that PFA0210c and its Plasmodium ortho-
logues contain an unusual C-terminal extension that regulates
the phospholipid transfer activity of the protein. Furthermore,
we provide evidence that the Plasmodium knowlesi orthologue
of PFA0210c, PKH_020910, is essential, and we apply new
genetic techniques to show that P. falciparum parasites lacking
PFA0210c do not develop or proliferate within the infected
erythrocyte. Additionally, we show that the regulation of phos-
pholipid transfer through the C-terminal extension is required
for parasite growth. Together, these experiments reveal a new
mechanism of regulating phospholipid transfer and show that
phospholipid transfer is an essential and regulated process in
Plasmodium parasites.
Results
PFA0210c and Its Orthologue in P. knowlesi Are Essential—
PFA0210c was initially identified as a conserved exported pro-
tein (29).We subsequently showed that PFA0210c as well as its
orthologues in the simian and human malaria pathogen
P. knowlesi (PKH_020910 or PKNH_0209300) and the
rodent parasite Plasmodium chabaudi (PCHAS_020730 or
PCHAS_0207300) are phospholipid transfer proteins that can
transfer a broad range of phospholipids in vitro (24). All three
proteins contain a signal sequence and a predicted PEXEL
motif that directs export from the parasite into the host eryth-
rocyte (Fig. 1A) (29–31). The proteins are characterized by a
poorly conserved N-terminal region, a START domain that is
required for the phospholipid transfer activity (24), and aC-ter-
minal extension of 84 amino acid residues (Fig. 1B). To gain
further insight into the function of this protein, we used the
recently developed P. knowlesi A.1-H.1 strain that has been
adapted to in vitro growth in human erythrocytes (32) to
attempt to generate a mutant that lacks the gene encoding
PKH_020910. The P. knowlesimodel is highly genetically trac-
table, allowing for rapid gene modification by homologous
recombination. We first confirmed that PKH_020910 is
expressed in in vitro culture by immunoblotting. Full-length
PKH_020910 has a predicted molecular mass of 55.4 kDa,
which is reduced to 52.7 kDa after removal of the signal
sequence and further reduced to 43.7 kDa after cleavage of the
PEXEL domain. Using an affinity-purified polyclonal antibody,
a protein of approximately the expected molecular mass was
detectable in extracts of infected erythrocytes (Fig. 2A) but not
in that of uninfected erythrocytes, despite the presence of a
higher amount of protein in the lane with uninfected erythro-
cyte extract (Fig. 2B). Immunofluorescence staining of erythro-
cytes infected with late stage parasites (schizonts) revealed that
the protein is likely expressed in a subset of apical organelles, as
indicated by the localized punctate pattern of staining (Fig. 2C).
The identity of this organelle could not be ascertained because
of the lack of organelle markers for P. knowlesi, and no signal
was obtained by immunoelectron microscopy using the avail-
able anti-PKH_020910 antibodies. Nonetheless, these experi-
ments confirmed that PKH_020910 is expressed in blood stages
of the P. knowlesi life cycle.
To determine whether PKH_020910 is required for parasite
growth, we attempted to disrupt the PKH_020910 gene
through single crossover homologous recombination (Fig. 3A).
Parasites were transfected with linearized plasmids that were
designed to integrate into the genome and either reconstitute
the entire gene or truncate the coding sequence to remove 46
residues of the START domain. A similar truncation of
PFA0210c ablates its capacity to transfer phospholipids in an in
vitro assay (24). After selection of the transfected parasites with
pyrimethamine, drug-resistant parasites were recovered in all
cases within 10–14 days. Diagnostic polymerase chain reaction
(PCR) analysis of genomic DNA (Fig. 3A) indicated that inte-
gration of the plasmid could only be detected in the case of the
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plasmids designed to reconstitute the entire open reading
frame (PKH_020910 476 in Fig. 3B); no integration was
detected in the plasmid designed to truncate the gene
(PKH_020910 346 in Fig. 3B). To rule out the unlikely scenario
that the different results reflected the different lengths of the
targeting region within the plasmids (972 bp versus 1362 bp),
we engineered a plasmid that contained the same 972-bp ho-
mology region as the deletion plasmid but also contained the
101 331 41537-411 27
97-101 161 392 4761 23
Signal
sequence START domain
C-terminal
extension
Non-conserved
N-terminal region
1 23 149 382 46661-65
PEXEL
P. falciparum PFA0210c
P. knowlesi PKH_020910
P. chabaudi PCHAS_020730
A
B
459453450447
418
468463456
428
346
FIGURE 1.Overview and alignment of the PFA0210c orthologues from P. falciparum, P. knowlesi (PKH_020910), and P. chabaudi (PCHAS_020730). A,
outline of the domains of PFA0210c and its orthologues, indicating the signal sequence (black), themotif thatmediates export to the erythrocyte (PEXEL; black
rectangle), the non-conserved N-terminal region (dark blue), the START domain (light blue), and the C-terminal extension (gray). Numbers above the outline
indicate the position of the amino acid residues at the start and end of the domains. The domain structure among the PFA0210c orthologues is the same,
although the length of the non-conserved N-terminal domain, and therefore the length of the entire protein, varies. B, alignment of PFA0210c with its
orthologues of P. knowlesi (PKH_020910) and P. chabaudi (PCHAS_020730). The START domain is underlined. Conserved residues in the C terminus that were
targeted in themutagenesis studies are shown in boldface type. The numbers at the end of the sequence indicate the position of the residue at the extreme C
terminus; the numbers above the sequence and the italicized numbers below the sequence indicate the position of the last residue of the truncations of the
P. falciparum and P. knowlesi protein, respectively, used in this study. Note that the variation in sequence length is determined by variation in the N-terminal
portion of the proteins; the length of the sequence from the start of the START domain to the C terminus varies by only two residues between these proteins.
Sequences were obtained from PlasmoDB (40) and aligned using Clustal Omega (45).
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remainder of the entire gene in a re-codonized form. Integra-
tion of this plasmid was thus mediated by the same targeting
sequence as the truncation plasmid but would lead to reconsti-
tution of the full-length gene. This plasmid readily integrated
into the chromosome (PKH_020910 346recodonized in Fig.
3B), indicating that the inability of the truncation to integrate
was not a consequence of the insufficient targeting sequence
but rather reflected a requirement for PKH_020910 for parasite
viability.
To avoid caveats associated with negative data, we wanted to
confirm further that this protein is required for parasite sur-
vival. We exploited a combination of recently developed Cas9
technology with conditional gene excision (33–36) to obtain an
inducible disruption of the gene in order to examine the essen-
tiality of PFA0210c in P. falciparum. For this, we replaced the
native PFA0210c open reading frame with a form interrupted
by a loxP-containing intron (37). This was followed by 855 bp of
a re-codonized PFA0210c-coding sequence plus a second loxP
site immediately following the stop codon (Fig. 4A). This gene
modification was performed in the 1G5DC P. falciparum clone
(38), which expresses the rapamycin-inducible Cre recombi-
nase (DiCre) (38, 39). Several transgenic parasite clones were
generated expressing the loxP-containing PFA0210c gene
(called PFA0210c-LoxP; Fig. 4B). Treatment of these clones
with rapamycin resulted in the expected excision of the seg-
ment of the PFA0210c gene that is flanked by the loxP sites (Fig.
4C). In confirmation of this, no PFA0210c protein could be
detected in schizonts of the rapamycin-treated parasites (Fig.
4D). To assess the effects of gene disruption on parasite viabil-
ity, growth assays were performed, comparing rapamycin-
treated PFA0210c-LoxP parasites with control mock-treated
counterparts. This revealed a severe growth defect in the para-
sites lacking PFA0210c (Fig. 4E), whereas treatment of 1G5 par-
asites with rapamycin did not affect their growth rate. Giemsa
staining of the parasites revealed that loss of PFA0210c resulted
in the formation of dysmorphic ring-stage parasites in the
growth cycle following that in which the parasites were treated
with rapamycin (the 60-h time point in Fig. 4F). These parasites
have a translucent, nearly white center and do not develop past
the ring stage, whereas DMSO-treated parasites and 1G5 para-
sites do develop into trophozoites (see the 76-h time point in
Fig. 4F). These results demonstrate that PKH_020910 and
PFA0210c are essential proteins in the asexual blood stage of
the Plasmodium life cycle.
PFA0210c and Its Orthologues Contain an Extended C
Terminus—The 84-residue C-terminal extension of PFA0210c
is highly unusual among START proteins. Although the 15
human START proteins range in size from 205 residues
(STARD5) to 4705 residues (STARD9), the START domain is
almost exclusively located at or very near the extreme C termi-
nus of the protein (Table 1); the longest C-terminal extension
found in a human STARTprotein, STARD10, is 50 residues. All
orthologues of PFA0210c possess a C-terminal extension rang-
ing from 81 residues in the Plasmodium yoelii orthologue
(PY17X_0210300) to 92 residues in the Plasmodium berghei
orthologue (PBANKA_0208900), withmost (including those of
PFA0210c, PKH_020910, and PCHAS_020730) comprising 84
residues (Table 1)). Sequence conservation in the C-terminal
extension is overall much lower than within the START
domain (Fig. 1B), However, we noticed the presence of a num-
ber of highly conserved residues near the extreme C terminus,
suggesting a conserved function (Fig. 1B).
C Terminus of PFA0210c Negatively Regulates Phospholipid
Transfer—To determine whether the C-terminal extension of
PFA0210c has a role in the regulation of its phospholipid trans-
fer activity, we produced recombinant forms of PFA0210c,
PKH_020910, and PCHAS_020730 that contained the entire
START domain but were truncated to various extents within
the C-terminal extension. The proteins were then compared in
an in vitro phospholipid transfer assay. All the truncated pro-
teins showedhigher phospholipid transfer activity than the full-
length protein, indicating that the C-terminal extension affects
the activity (Fig. 5A).
To investigate whether the observed regulation through the
C terminus was mediated simply through steric hindrance by a
large protein domain or whether it required the presence of a
conserved sequence-specific element in the C terminus, we
replaced the C-terminal 48 residues of PFA0210c (the residues
absent from the truncated version of the protein used in Fig.
4A) with either the corresponding sequence of the P. chabaudi
orthologue or the C-terminal 48 residues of green fluorescent
protein (GFP). The chimeric protein containing C-terminal
residues of the P. chabaudi orthologue displayed levels of phos-
pholipid transfer activity similar to that of full-length wild type
PFA0210c, whereas the form containing the GFP sequence
showed increased activity, similar to that of the truncated
250
98
64
50
36
16
A
B
CUninf. Inf.
250
98
Uninf. Inf.
DIC
DIC
Anti-PKH
DAPI
Anti-PKH
DAPI
Anti-PKH
FIGURE 2. PKH_020910 is produced during the asexual intraerythrocytic
life cycle.A, immunoblot using anti-PKH_020910 antiserumprobing extracts
of either uninfected erythrocytes (Uninf.) or erythrocytes infected with
P. knowlesi (Inf.). B, immunoblot using anti-spectrin antibodies of the same
extracts as in A. The more intense band in the uninfected lane indicates that
more cell equivalents were loaded in the lane containing the extract of unin-
fected erythrocytes. C, detection of PKH_020910 in infected erythrocytes by
indirect immunofluorescence microscopy. Erythrocytes infected with late-
stage P. knowlesiwere stained with anti-PKH_020910 antiserum and DAPI to
visualize the parasite nuclei. Staining is clearly visible within the parasites but
is absent in uninfected erythrocytes. DIC, differential interference contrast.
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PFA0210c (Fig. 5B). These results suggest that regulation of
phospholipid transfer activity involves conserved sequence ele-
ments in the C-terminal extension. We conclude from these
experiments that the C-terminal extension of PFA0210c and its
orthologues contains one or more conserved sequence-specific
elements that regulate the phospholipid transfer activity of the
proteins.
Regulation through the C Terminus Is Confined to a Short
Conserved Region—Wenextwanted to define inmore detail the
region of the C terminus that mediates the regulation of phos-
pholipid transfer. As the sequence conservation is primarily
restricted to the C-terminal 27 residues of the protein (Fig. 1B),
we focused on this region. To identify the residues involved in
the regulation of phospholipid transfer activity, we produced
serially truncated versions of recombinant PFA0210c that
sequentially removed three to six residues (see Fig. 1B for the
positions where the proteins were truncated) and evaluated the
effects on in vitro phospholipid transfer activity. This revealed
that removal of the last 19 residues (C-terminal residue 447),
which includes the highly conserved residues fromposition 448
through 466, produced fully active protein (Fig. 6A). Truncated
proteins that lacked between 16 and 13 residues (C-terminal
residues 450 and 453, respectively) displayed low activity that
was nonetheless higher than that of the full-length protein. A
truncation of only seven residues (C-terminal residue 459) had
no effect on activity relative to the full-length protein (C-termi-
nal residue 466).
These results show that the phospholipid transfer activity of
PFA0210c is regulated through a short patch of residues near
the extreme C terminus, extending from Trp-448 to Lys-457.
These residues are conserved in P. falciparum and P. knowlesi
but not in the rodent malaria species (Fig. 1B). However, the
Ile-448 and Trp-449 as well as the Lys residue nine residues
downstream that are all part of the conserved region in
PFA0210c are also present in the rodent malaria parasite spe-
cies, albeit shifted by 12 residues compared with the non-ro-
dent malaria parasites. This suggests that the positioning of the
regulatory region is shifted slightly in the rodent malaria
parasites.
To understand the roles of the conserved residues in more
detail, we separately substituted the conserved Trp-448 and
Ile-449 residues as well as Lys-456 and Lys-457 in PFA0210c
(see boldface residues in Fig. 1B) into full-length and truncated
recombinant proteins. Phospholipid transfer analysis of these
mutants revealed that substitution of Trp-448 and Ile-449 in
the protein truncated at residue 450 resulted in gain-of-
transfer activity, producing activity similar to that of the
protein truncated at residue 447. However, the same muta-
tion in the protein that contains an additional nine residues
(C-terminal residue 459) did not result in an increase in
activity. Mutation of Lys-456 and Lys-457 did not affect
phospholipid transfer activity of either full-length or trun-
cated proteins.
1
1 2 3
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4
4
PKH_020910
PbDT 3’ UTR
A
B
Plasmid
Wild type locus
Integrated plasmid
Primers 1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
P. knowlesi untransfected PKH_020910 476 PKH_020910 346 PKH_020910 346+recodonized
1000
800
1500
2000
2500
FIGURE 3.PKH_020910 is essential in P. knowlesi.A, outline of the transfection strategy and location of the primers used for the verification of integration of
the plasmids. The plasmid containing the fragment of PKH_020910 was linearized with BsaBI within the PKH_020910 coding sequence to promote recombi-
nation and prevent plasmid propagation. Note that the 5 region of PKH_020910 that encodes the signal sequence was omitted from the integration region.
The duplicated copy of PKH_020910 produced following integration therefore lacks a start codon and cannot give rise to an exported protein. The plasmid
backbone is shown in purple. B, verification of integration of the PKH_020910 targeting plasmids using the primers shown in A. Integration-specific products
were detected only with DNA from parasites transfected with targeting vectors that would reconstitute the entire gene (PKH_020910 476 and PKH_020910
428recodonized) and not with the targeting vector designed to truncate the gene to produce a non-functional protein or with DNA from untransfected
parasites. The number after the gene name indicates the last codon of PKH_020910 in the targeting region. Expected sizes of the PCR products are as follows:
12,1469 bp; 34, 1919 bp; 15, 1453 bp; 14, 1892 bp. Sizes of relevant standards are indicated on the left-hand side. All transfections were repeated a
minimum of three times, each time yielding the same result.
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To test whether the two Lys residues by themselves pro-
vide the additional regulation in proteins lacking the Trp-
448 and Ile-449 residues, we produced a mutant protein that
contained both sets of mutations (this mutant also lacks the
last seven residues, as full-length protein with the Trp-448
and Ile-449 mutation could not be obtained in a non-aggre-
gated form). However, this double mutant protein did not
display enhanced activity above that of the wild type protein.
Together, these results show that the phospholipid transfer
activity of PFA0210c is regulated by specific residues in the
extreme C-terminal 18-residue segment of the protein. The
Trp-448 and Ile-449 residues play a pivotal role in this regula-
tion, but additional residues are also involved.
Regulation of Phospholipid Transfer Activity Is Required in
Vivo—Having shown that the phospholipid transfer protein is
required for growth of the parasite, we next wanted to deter-
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FIGURE 4. Inducible removal of PFA0210c in P. falciparum leads to rapid death of the parasite. A, integration strategy for the replacement of the native
PFA0210c locus with a version of the gene containing two loxP sites. Three separate guide RNAs were used to facilitate integration of into the native gene.
Induction of Cre recombinase activity by the addition of rapamycin induces the excision of the sequence between the two loxP sites. B, diagnostic PCR of wild
type P. falciparum and PFA0210c-LoxP clones A8, C12, and C18 using primers specific for either the native sequence or the integrated re-codonized sequence.
PrimersusedareCVO150 (1) andCVO083 (2) (5N), CVO150andCVO162 (5) (5 I), CVO071 (3) andCVO183 (4) (3N), andCVO321 (6) andCVO183 (3 I).N indicates
primer pair specific for native locus, and I indicates primer pair specific for the integrated PFA0210-LoxP. C, verification of excision after addition of rapamycin
in clonesA8, C12, andC18. Parasiteswere treatedwith 10nM rapamycin or an equivalent volumeofDMSO for 1h. Forty hours later genomicDNAwas extracted
and used as template for PCR with primers 7 (CVO001) and 8 (CVO097). Successful excision decreases the size of the expected band from 1536 to 561 bp. D,
immunoblot using anti-PFA0210c antibodies shows that rapamycin (Rapa)-treated parasites lack PFA0210c. Parasites were treated early in the ring stage, and
proteins were extracted 40 h later. E, growth rate of the parasites lacking PFA0210c is severely decreased. Parasites containing PFA0210c-LoxP or the
DiCre-expressing parent clone were synchronized in the early ring stage and diluted to a parasitemia of0.6%. The parasites were then treated with 10 nM
rapamycin or the equivalent volume of DMSO for 1 h. Parasitemia wasmeasured immediately before treatment (cycle 1), 76 h after diluting (cycle 2), and 96 h
after diluting. Parasite cultureswere set up in triplicate. Error bars indicate standard deviation. F,parasites lacking PFA0210c form aberrant ring-stage parasites
and do not develop past the ring stage. Parasites used in Ewere used to make Giemsa-stained smears at the times indicated. Parasites from the parent clone
appear normal, as do the DMSO-treated PFA0210c-LoxP parasites. PFA0210c-LoxP parasites treatedwith rapamycin form small rings with vacuolated centers.
At the 76-h time point, these parasites have not developed further, in contrast to the parent strain or the DMSO-treated PFA0210c-LoxP strain.
TABLE 1
Location of START domains in human START-domain-containing proteins and PFA0210c orthologues
Information was obtained from the NCBI protein resource. Proteins are grouped as described (5, 6).
Family Name Length (amino acids) START domain (amino acids) Extension
Human
Cholesterol/sterol carrier StarD1 (StAR) 285 67–280 5
StarD3a 445 233–441 4
StarD4b 205 5–205 0
StarD5 213 6–211 2
StarD6 220 1–204 16
Sphingolipid/glycerolipid carriers StarD2 (PCTP) 214 4–210 4
StarD7c 370 117–325 45
StarD7d 269 16–224 45
StarD10 291 19–241 50
StarD11 (CERT) 598 364–598 0
Rho-GAP START domains StarD12 (DLC-1)e 1528 1315–1518 10
StarD13 (DLC-2)f 1124 911–1115 9
StarD8g 1107 894–1098 9
Thioesterase START domains StarD14 (BFIT) 607 344–583 24
StarD15 (CACH) 555 311–546 9
Other StarD9h 4705 4496–4705 0
Plasmodium spp.
P. falciparum PFA0210c 466 149–382 84
P. chabaudi PCHAS_020730 415 101–331 84
P. knowlesi PKH_020910 476 161–392 84
P. berghei PBANKA_0208900 441 118–349 92
P. yoelii PY17X_0210300 431 119–350 81
P. vivax PVX_081550 495 179–410 85
a This is isoform 1.
b This is isoform a.
c This is isoform CRA_a.
d This is mitochondrial isoform X1.
e This is isoform 1.
f This is isoform X2.
g This is isoform X2.
h This is isoform X1
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FIGURE 5.C-terminal extension of PFA0210c and its orthologues regulates phospholipid transfer. A, phospholipid transfer activity of full-length (FL) and
truncated (Trunc.) PFA0210c, PKH_020910, and PCHAS_020730. Phospholipid transfer was measured using an activity assay that measures the transfer of
radiolabeled phosphatidylcholine from a small population of donor vesicles to a larger population of acceptor vesicles. B, phospholipid transfer activity of
full-length PFA0210c (FL), truncated PFA0210c (Trunc.), and PFA0210c where the last 48 amino acid residues have been replaced with the corresponding 48
residues from PCHAS_020730 (Pc C term.) or GFP (GFP-C term.). All assays were performed in triplicate. Error bars indicate standard deviation.
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mine whether the regulation of phospholipid transfer revealed
through the in vitro experiments is functionally important in
vivo. For this, we used the same integration strategy as
described in Fig. 3A to attempt to introduce serial truncations
of PKH_020910 in the P. knowlesi genome. Integration of the
various targeting plasmids used was designed to produce trun-
cated genes encoding proteins lacking the C-terminal eight res-
idues (retaining all the residues required for the regulation of
the phospholipid transfer activity in vitro), 13 residues (thereby
removing some but not all of the regulatory residues), or 20
residues (thereby removing all of the regulatory residues). In
addition, we used a plasmid that upon integration would pro-
duce a gene that encodes a protein lacking internal residues
433–444 of the C-terminal extension (12), thus shortening
the C-terminal extension but retaining the regulatory residues
at the extremeC terminus. Parasiteswere recovered after trans-
fection with each plasmid, and integration was determined
using the same strategy as described in Fig. 1. This revealed that
the positive control plasmid designed to reconstitute the entire
gene readily integrated (Fig. 7). However, integration of none of
the plasmids designed to give rise to a truncated protein was
detected. These results indicate that regulation of phospholipid
transfer by the protein is required for parasite growth.
Surprisingly, the plasmid designed to give rise to a protein
lacking 12 residues of the C-terminal extension but containing
the conserved region at the end of the C terminus readily inte-
grated. It thus appears that the residues at the extreme C ter-
minus of PKH_020910 are required for regulation but that their
distance from the end of the START domain may vary.
Discussion
In this work, we have shown that the START protein
PFA0210c and its orthologues are required for the growth of
the malaria parasite in its clinically relevant blood stages.
Replacement of the native gene with a version that encodes a
protein that cannot transfer phospholipids was not successful
in P. knowlesi, whereas control plasmids readily integrated,
strongly suggesting that parasites lacking a functional gene are
not viable. Furthermore, conditional disruption of the
PFA0210c gene in P. falciparum blocked the development of
the parasites in the subsequent round of replication. Further
support for the essential nature of the protein is that genetic
modification of the orthologous gene in P. berghei was unsuc-
cessful, as listed on PlasmoDB (www.plasmodb.org (40)).
Additional in vitro analysis showed that PFA0210c is regu-
lated through a unique C-terminal extension. The residues
responsible for the regulation lie close to the extreme C termi-
nus and are conserved among the Plasmodium orthologues.
This conservation of sequence is supported by the demonstra-
tion that the correspondingP. chabaudi sequence could restore
regulation of the P. falciparum orthologue PFA0210c in vitro,
whereas replacement of the C terminus with the equivalent
sequence from GFP did not affect the regulation. In further
experiments, the presence of the C-terminal 48 residues of
PFA0210c in the form of a separate peptide or a glutathione
S-transferase (GST) fusion protein did not affect phospholipid
transfer levels of truncated PFA0210c, indicating that the reg-
ulatory function of the C-terminal sequence cannot be medi-
ated in trans, although we cannot rule out that the GST fusion
and the peptide were not in the correct conformation to medi-
ate their effect. Importantly, this regulation is likely to be essen-
tial for parasite viability, as wewere unable to obtainP. knowlesi
parasites expressing a truncated version of the protein. The
precise location of the regulatory region relative to the end of
the START domain appears to be somewhat flexible, as replac-
ing the native gene with a version that encodes a protein in
which the extreme C terminus is shifted 12 residues closer to
the STARTdomain appeared to be tolerated in vivo. Consistent
with this, in the rodent malaria parasite orthologues, residues
that are highly conserved in the non-rodent malaria parasites,
are shifted by 12 residues. Interestingly, we could not obtain
viable parasites that expressed a version of the protein that
lacked the C-terminal eight amino acids but retained the resi-
dues that are important for regulating phospholipid transfer in
vitro. Hence, in vivo the regulation of phospholipid transfer by
PFA0210c and its orthologues may be more complex. We
hypothesize that there are two regulatory regions as follows: the
first region bounded by the Trp-448 and Ile-449 and the Lys
residues at position 456 and 457 that was identified in the in
vitro assay as the negative regulatory region (the WI-KK
domain); and a second region, closer to theC terminus, that can
counteract the negative regulation mediated by the WI-KK
domain upon a signal from another source. Hence, removing
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FIGURE 6. Small conserved region in the C terminus regulates phospholipid transfer. A, phospholipid transfer activity of truncated forms of PFA0210c in
vitro. Numbers indicate the C-terminal residue in the truncations. B, phospholipid transfer activity of point mutations in truncated proteins and full-length
mutations. Indicated are the C terminus and in parentheses the point mutations (see Fig. 1B for location of mutated residues). C, phospholipid transfer activity
of a double mutant and control proteins. All assays were performed in triplicate. Error bars indicate standard deviation.
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this second region would make the protein permanently inac-
tive, as the regulation mediated by the WI-KK domain cannot
be removed. The protein is essential for the growth of the par-
asite, and therefore, removing its capacity to activate phospho-
lipid transfer activity would be a lethal event for the parasite.
Potentially, a cofactor is required that interacts with the second
region to counteract the negative regulation of the WI-KK
domain in the transfer of phospholipids. This would allow for
the intriguing possibility that this cofactor regulates the direc-
tionality of phospholipid transfer; the protein would only be
able to obtain and/or release its phospholipid to amembrane in
which the cofactor is present. Identification of a binding part-
ner of PFA0210c would shed light on this model.
This report is only the second to provide evidence for regu-
lation of the activity of a mammalian START protein. The only
other example is that of STARD10, which similarly contains a
C-terminal extension, albeit shorter (50 amino acids compared
with 86 amino acids in PFA0210c; Table 1). This C-terminal
extension is phosphorylated in vivo, whereas phosphorylation
in vitrowith casein kinase II decreased its phospholipid transfer
activity (18). Interestingly, an eight-amino acid truncation of
STARD10, removing the phosphorylation site, increased its
activity beyond that of the unphosphorylated protein. It was
initially speculated that phosphorylation of the protein may
decrease the binding of STARD10 tomembranes, but in light of
the results presented here, it may also be possible that phos-
phorylation of the protein induces a conformational shift that
reduces activity. This may point to a broader regulation of
START proteins that contain a C-terminal extension. In con-
junction with the previous report (18), this study begins to elu-
cidate a mechanism by which phospholipid transfer can be
regulated in vivo, a mechanism potentially shared from Api-
complexa to humans.
Experimental Procedures
Parasite Culture and Transfection—The human-adapted
P. knowlesi clone A.1-H.1 was cultured as described (32).
Briefly, parasites were maintained in human erythrocytes (2%
hematocrit) in RPMI 1640medium supplementedwith 2.3 g/li-
ter sodium bicarbonate, 4 g/liter dextrose, 5.957 g/liter HEPES,
0.05 g/liter hypoxanthine, 5 g/liter Albumax II, 0.025 g/liter
gentamycin sulfate, 0.292 g/liter L-glutamine, and 10% (v/v)
horse serum.
For transfections of P. knowlesi, parasites were transfected
using the Amaxa 4D electroporator (Lonza), as described pre-
viously (32, 41). Late stage parasites were harvested by flotation
on a 55% Nycodenz (Axis-Shield) stock solution (consisting of
27.6% (w/v) Nycodenz powder in RPMI 1640 medium). Puri-
fied parasites were maintained in RPMI 1640 medium until a
majority had reached the eight-nuclei stage. The parasites were
then centrifuged briefly, and the supernatantwas removed. The
parasites were suspended in 100 l of nucleofection solution
(P3 Primary cell 4DNucleofector X Kit L (Lonza)), and 10l of
TE containing50g of plasmid that had been linearized with
BsaBI was added, and the parasites were subsequently electro-
porated. Parasites were transferred to a flask containing 300 l
of blood and 1.7 ml of RPMI 1640 medium and maintained,
with shaking, for 30 min at 37 °C to allow for efficient invasion.
Eight ml of medium was added, and the parasites were further
maintained at 37 °C. Selection for transfected parasites with 0.1
M pyrimethamine was initiated 20 h after transfection.
Drug-resistant parasites were usually detected 10–14 days
later.
Integration of plasmids in P. knowlesi was determined by
isolating genomic DNA from the parasites using the Qiagen
Blood and Tissue kit and using the extracted DNA as tem-
plate for PCR using primer pairs specific for the integrated
plasmid (CVO093 and CVO079, M13 reverse, and CVO104),
the wild type locus (CVO093 and CVO104), and circularized
plasmid (M13 reverse and CVO079) as described under
“Results.” All primer sequences are listed in Table 2. The
1G5DC clone and the PFA0210c-LoxP strain of P. falcipa-
rum 3D7 were maintained as P. knowlesi, without the addi-
tion of human serum.
Generation of the inducible PFA0210c-LoxP strain in the
1G5 background was conducted using the CRISPR/Cas9 sys-
tem. Schizonts of the 1G5DC strain were transfected according
to standard protocol (38) with pBLD529 (the plasmid that
introduces the LoxP sites, see below) and the Cas9-expressing
pDC2-cam-Cas9-U6-hDHFR (42) plasmid to which the gene
encoding the yeast cytosine deaminase-uracil phosphoribosyl-
transferase had been added, as well as a sequence encoding
guide RNAs specific for PFA0210c. Transfectants were initially
selected with 2.5 nM WR99210 and were subsequently treated
with 1 M ancotil to select against parasites carrying the pDC-
Primers 1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
1+2 3+4 1+5 1+4
Integration Wild type
800
1000
1500
2000
2500
PKH_020910 full length PKH_020910 468 PKH_020910 463 PKH_020910 456 PKH_020910 Δ12
FIGURE 7. Regulation of phospholipid transfer is required in vivo. Diagnostic PCR analysis of attempted integration of truncation plasmids designed to
remove 8 codons (PKH_020910 468), 13 codons (PKH_020910 463), or 20 codons (PKH_020910 456) from the end of the gene encoding PKH_020910 or to
remove internal codons 433–444 (PKH_020910 12). Integration-specific PCR products were detected only in parasites that reconstituted the entire gene
(PKH_020910 full length) and PKH_02091012. The PCR strategy and the primers used are described in Fig. 3A. All transfections were repeated aminimumof
three times, each time yielding the same result.
Regulation of a Phospholipid Transfer Protein
24288 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 46•NOVEMBER 11, 2016
 at LO
N
D
O
N
 SCH
 O
F H
Y
G
IEN
E &
 TRO
PICA
L M
ED
ICIN
E on M
arch 5, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
based plasmid. Ancotil-resistant parasites were cloned by lim-
iting dilution.
Integration of the plasmid and recombination of PFA0210-
LoxP were determined as for P. knowlesi, using primer pairs
CVO150 with CVO083 and CVO071 with CVO183 to test the
presence of the wild type gene, CVO150 with CVO162 and
CVO321 with CVO183 to determine integration of the plas-
mid. Removal of the gene after rapamycin treatment was deter-
mined by PCR using primers CVO001 and CVO097.
To induce Cre recombinase activity, parasites in the early
ring stage were incubated at 37 °C in the presence of 10 nM
rapamycin (added from stocks in DMSO) or the equivalent vol-
ume of DMSO as control. After 30–60 min, the parasites were
washed once and resuspended in growth medium.
Parasitemia was determined by cell counting using a FACSAria
fusion flow cytometer. First,2 l of infected cell culture was
fixed with 0.2% glutaraldehyde in PBS for 1 h and subsequently
washed with PBS and stored at 4 °C. Prior to counting, the cells
were stained with 2 M Hoechst 33342 in PBS for 30 min. The
number of infected erythrocytes per 50,000 erythrocytes was
determined.
Immunoblotting and Immunofluorescence Imaging—To
detect PKH_020910 and PFA0210c by immunoblotting,
extracts of uninfected erythrocytes and erythrocytes infected
with schizont stage parasites were produced by suspending the
cell pellet in 3 volumes of 1 SDS loading dye and separating
the proteins on a SDS-12.5% polyacrylamide gel. The proteins
were transferred to nitrocellulose, and after blocking the blot
with 5%milk in PBS containing 0.05%Tween, the proteinswere
detected by incubating the blot with the affinity-purified anti-
PKH_020910 or anti-PFA0210c antibody at a dilution of 1:5000
or 1:2500, respectively. Antibody binding was visualized by
incubating the blot withHRP-linked goat anti-rabbit secondary
antibody and developing with ImmobilonWestern chemilumi-
TABLE 2
Primers used in this study
Restriction sites are shown in lowercase.
CVO010 GGACctcgagTCAGAAGATGCTGGTAACGATAACGTAAATTTTTTTG
CVO014 GGACgaattcGTCAGAGAAATAAACGGAAATGATG
CVO015 GGACctcgagTCAGTGATGGTGATGGTGATGGAAGATGCTGGTAACGATAACGTAAATTTTTTTG
CVO021 GGACctcgagTCAGTGATGGTGATGGTGATGTGGAGTATCTTCTGGCTTAACGTTTTTTAAACTATGTG
CVO022 GGACgaattcAAAAGTGCAACTTTAATAAATGATGGTATGTTAGAT
CVO054 GGACctcgagTCAGTGATGGTGATGGTGATGATAAGAATTTTCTGGATCCGTTTGTAC
CVO057 GGACctcgagTCAGTGATGGTGATGGTGATGAAATATTTTTTTAAAAAAGTTAACGTTGATGATCC
CVO059 GGACtctagaAAGGAAAACCAAAAATATTTAGAACAAGCTAAG
CVO060 GGACctcgagTCAGTGATGGTGATGGTGATGTTCATCATATTGGAACATACCAAATG
CVO061 GGACctcgagTCAGTGATGGTGATGGTGATGATTTTCGACTGATTTAAGTTTTTTATTATGGG
CVO064 GGACctcgagTTAGTGATGGTGATGGTGATGTCCCGCCAATCCACCAGC
CVO065 CTAAAGCGTTTTCTGAACTATTTAATTTTGGAGTATCTTCTGGCTTAACGTTTTTTAAACTATGTG
CVO066 CACATAGTTTAAAAAACGTTAAGCCAGAAGATACTCCAAAATTAAATAGTTCAGAAAACGCTTTAG
CVO067 CTTAAATAATGATTATCTGGTAATAATACAGGTCCTGGAGTATCTTCTGGCTTAACGTTTTTTAAACTATGTG
CVO068 CACATAGTTTAAAAAACGTTAAGCCAGAAGATACTCCAGGACCTGTATTATTACCAGATAATCATTATTTAAG
CVO069 GGACctcgagTCAGTGATGGTGATGGTGATGTTTATATAATTCATCCATTCCTAAAGTAATACC
CVO071 GGACgaattcATAGCCATCACAAATAAAACTGTAGGAAC
CVO079 AACGAACATTAAGCTGCCATATCC
CVO083 GGATAACTTCGTATAATGTATGCTATACGAAGTTATCGTTCTTAAATTTACTGCTGCATTTTCTAAACTCC
CVO093 GGACgaattcATGATTTTAAAAAAAAGCAAACTGCTTGCACTC
CVO097 CATTTAAACCTTTCCAATATCACACATTTGC
CVO104 GGTTTCCCCCTCCTTTTCAGC
CVO121 GCACccgcggTGGGTAGAGGCAGAAAAAATTCTCG
CVO122 GCACccgcggTCAGAAGATGCTGGTAACGATAACGTAAATTTTTTTG
CVO123 GCACcccgggCGAGATGGACGACGCAAATGGATGAGTCTGC
CVO150 ATTTTATATGCTTTAGGTTATTCGTAGACAGTG
CVO162 CTTGGTACGCAGGTTCACAGCAG
CVO163 ttacaaaatgcttaaGGTGAGACAAGTATAGATTTAAACTATTTTGGCTGG
CVO183 ttacaaaatgcttaaCACATGCGCATTTTCACCAATTTTTGCC
CVO237 GCACccgcggTCAAATTTTTTTGAAAAAATTGACATTGGTGGTCCAAATG
CVO238 GCACccgcggTCAATTGGTGGTCCAAATGAAGTAGAAGG
CVO239 GCACccgcggTCAGAAGTAGAAGGGGTCCACGAAG
CVO240 CGAAGATGACGCGGAGGACATCCATTCCCGCCAATCCACCAGC
CVO241 GCTGGTGGATTGGCGGGAATGGATGTCCTCCGCGTCATCTTCG
CVO254 ATAACTTCGTATAATGTATGCTATACGAAGTTATTTAGTCCTTGTTGAAGAAGATGCCGAAGATCTTC
CVO305 GGACTAAATAACTTCGTATAGCATACATTATACGAAGTTATGCAAATGTGTGATATTGGAAAGG
CVO306 CGAAGTTATGCAAATGTGTGATATTGGAAAGGTTTAAATGAAAATATGTAAATCG
CVO321 GCCTGAGGACACCCCCAACACC
CVO426 GGACaagcctTTAGTGGTGGTGGTGGTGGTG AAATATTCCTTCAAAAAAGTTAACGTTGATGATCC
CVO427 GGACaagcttTTAGTGGTGGTGGTGGTGGTG AAATATTTTTTTAAAAAAGTTAACGTTGATTCCTTC
CVO428 GGACaagcttTTAGTGGTGGTGGTGGTGGTGGATTCCTTCTAAATTATAAGGGCCATCAACAAATATC
CVO451 GGACaagcttTTAGTGGTGGTGGTGGTGGTGAAATATTCCTTCAAAAAAGTTAACGTTGATCTGGCT
RJH19 GAAGGAATATTTGGTATATTTTTTAATAAGGACTAA
RJH20 AAAAAATATACCAAATATTCCTTCAAAAAAGTTAACGTTGATGATCCATAAATTATAAGGGCC
RJH21 AGCCAGATCAACGTTAACTTTTTTAAAAAAATATTTGGTATATTTTTTAATAAGGAC
RJH22 TATTTTTTTAAAAAAGTTAACGTTGATCTGGCTTAAATTATAAGGGCCATCAACAAATATCATTTTAATAAA
RJH23 GGACaagcttCTAGTGATGGTGATGGTGATGGATGATCCATAAATTATAAGGGCCATCAACAAA
RJH24 GGACaagcttCTAGTGATGGTGATGGTGATGTAAATTATAAGGGCCATCAACAAATATCATTTTAATAAAACC
RJH40 GTCCCCGCGGTTAGAAAATGCTGGTAACAATCACATATATCTTCTTAAA
RJH41 GAGAATTTTTTCTGCCTCTACCCAAAAAATAAAAACAGTTATGAGAAGGGCCTGGAT
RJH42 CTTCTCATAACTGTTTTTATTTTTTGGGTAGAGGCAGAAAAAATTCTCGTAATCACGTAT
PFA0210 5-23 GGACgaattcGATAAAGAGAATACAGCAAGTTTTATAAAAACTGGT
PFA0210 3-26 GGACctcgagTTAGTGGTGGTGGTGGTGGTGGTCCTTATTAAAAAATATACCAAATATTTTTTTAAAAAAGTTAAC
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nescent HRP substrate (Millipore). Spectrin was detected using
an anti-spectrin ( and ) mousemonoclonal antibody (Sigma)
and an HRP-linked goat anti-rabbit secondary antibody.
Immunofluorescence imaging was performed as described
(43). A small aliquot of infected erythrocytes was spun down
and resuspended in PBS containing 4% paraformaldehyde and
0.01% glutaraldehyde. After 1 h of agitation at room tempera-
ture, the parasitized erythrocytes were pelleted, washed with
PBS, permeabilized with 0.1% Triton X-100 for 15min, washed
once more with PBS, blocked with 3% BSA in PBS, and then
incubated for 1 h at room temperature in PBS containing 3%
BSA and anti-PKH_020910 antibody diluted at 1:5000. The
erythrocytes were then washed three times with PBS and sub-
sequently incubated at room temperature in PBS containing 1
g/ml 4,6-diamidino-2-phenylindole (DAPI) and Alexa 596-
conjugated anti-rabbit antibodies diluted at 1:5000 for 1 h. The
erythrocyteswerewashed three timeswith PBS, resuspended in
a small volume of PBS, and placed on a polyethyleneimine-
coated microscope slide. This was covered with a coverslip and
sealed with nail polish. Differential interference contrast and
fluorescence imageswere obtained on aNikon EclipseNi, fitted
with a Hamamatsu C11440 digital camera. Images were pro-
cessed in Photoshop. Note that the anti-PKH020730 signal was
false colored green.
Production of Plasmids—Plasmids used for disrupting the
PKH_020910 locus were produced by amplifying the region of
PKH_020910 to be targeted (omitting the first 22 codons of the
genomic sequence) by PCR. The resulting fragment was cloned
into the XmaI and SacII sites of pHH4-MyoA-GFP (32), pro-
ducing the plasmids pBLD468 (product of primers CVO123
and CVO122, ending at codon 476 (full length)), pBLD481
(product of primers CVO123 and CVO237, ending at codon
468), pBLD482 (product of primers CVO123 and CVO238,
ending at codon 461), pBLD483 (product of primers CVO123
and CVO239, ending at codon 456), and pBLD467 (product of
primers CVO123 and CVO121, ending at codon 336). Plasmid
pRH34, which contains a fusion of the sequence in pBLD467
and a re-codonized version of the remaining coding sequence,
was produced by overlapping PCR. The wild type gene (ending
at codon 367) was amplified from genomic P. knowlesi DNA
(using primers CVO123 and RJH42), and the remaining
sequence (codons 368–476) was amplified by PCR using a ver-
sion of the gene codon-optimized for Escherichia coli
(GeneArt) (using primers RJH41 and RJH40). The two frag-
ments were fused by PCR, using built-in overlapping ends and
primers CVO123 and RJH040. Plasmid pBLD484, which lacks
codons 433–444, was also made by overlapping PCR, using
primers that amplified codons 23–432 (CVO123 andCVO241)
and codons 445–476 with overlapping ends (CVO240 and
CVO122). The fragments were fused by PCR using the internal
overlap and primers CVO123 and CVO122.
Plasmid pBLD529 that was used to replace the native
PFA0210c gene with a version containing the SERA2 intron
containing a loxP site was created as follows. A synthetic gene
product containing a fusion of wild type sequence and re-
codonized sequence was cloned into the pBAD vector. This
sequence was fused to 3 UTR sequence of PFA0210c by over-
lapping PCR using primer pairs CVO001 and CVO254 (com-
bined with CVO305 to add the LoxP site) to amplify the coding
region and CVO306 and CVO163 to amplify the 3 region. The
overlapping PCR introduced a loxP site immediately following
the stop codon. This sequence was cloned into pGEM-T by
T-tailing, creating pBLD509. To introduce the loxP site con-
tained in the SERA2 intron, a synthetic DNA fragment was
obtained that contained wild type PFA0210c sequence fused
with PFA0210c re-codonized sequence containing a SERA2
intron inwhich a loxP sitewas inserted between bp 463 and 464.
A SpeI-Tth111I fragment of this fusion was cloned into
pBLD509 to give rise to pBLD529.
Plasmids used for protein production in E. coli were pro-
duced as follows. As the N-terminal region of PFA0210c does
not affect the phospholipid transfer activity of PFA0210c (24), it
was not included in the recombinant proteins (“full-length”
denotes the presence of the entire C-terminal extension). Gene
fragments starting at codon 144 in PFA0210c, codon 111 in
PKH_020910, and codon 49 in PCHAS_020730 were amplified
from genomic DNA using primer pairs PFA0210c 5-23
and PFA0210c 3-26 (PFA0210c), CVO014 and CVO015
(PKH_020910), and CVO059 and CVO060 (PCHAS_020730),
respectively, and cloned into either the EcoRI (PFA0210c and
PKH_020910) or the XbaI (PCHAS_020730) and the SalI site of
pMAL c2x (New England Biolabs). Truncated versions of
PFA0210c, PKH_020910, and PCHAS_020730 were produced
using primer pairs CVO022 and CVO021, CVO014 and
CVO064, and CVO059 and CVO61, respectively. To produce
the serial truncations of PFA0210c, DNA was amplified with
primer CVO022 paired with primer CV057 (terminal codon
459, plasmid pBLD413), primer CVO056 (terminal codon 453,
plasmid pBLD412) or primer RJH023 (terminal codon 450,
plasmid pRH17), and primer RJH024 (terminal codon
447, plasmid pRH18), and the resulting DNA was cloned into
the EcoRI and HindIII sites of pMAL c2x. Each 3 primer con-
tained the sequence of a hexahistidine tag, hence the resulting
protein contained the maltose-binding protein at the N termi-
nus and a hexahistidine tag at the C terminus. The fusions of
PFA0210c with the C terminus of PCHAS_020730 or the C
terminus of GFP were produced by overlapping PCR. The
region of PFA0210c encompassing codon 144–418 was ampli-
fied from genomic DNA using primers CVO022 paired with
CVO065 for the fusion with PCHAS_020730 and CVO067 for
the fusionwithGFP,with an overlapping tail complementary to
the fragment to be fused. The PCHAS_020730 fragment, span-
ning codons 368–415, was amplified by PCR using genomic
P. chabaudi DNA as template using primers CVO065 and
CVO060. The GFP fragment, spanning codons 194–241, was
amplified by PCR using the gene encoding enhanced GFP as
template using primers CVO068 and CVO069 and fused to
the PFA0210c fragment by overlapping PCR using primers
CVO022 and CVO069.
Point mutations were generated by overlapping PCR. The 5
regionwas generated using primer CVO022 pairedwith primer
RJH019 (KK-EG) or RJH021 (WI-SQ), whereas the 3 region
was generated using primers RJH020 (KK-EG) or RJH022
(WI-SQ) paired withM13 forward. DNA fragments were fused
by PCR using primers CVO022 and M13 forward using the 5
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and 3 region as template and cloned into pMAL c2x using
EcoRI and HindIII.
To introduce these point mutations into truncated genes,
the genes were amplified using primers CVO022 paired with
CVO426 (terminal codon 459, KK-EG mutation) using
pBLD413 (which contains the gene encoding PFA0210c with
codon 459 as terminal codon) as template, CVO427 (terminal
codon 459,WI-SQmutation), orCVO428 (terminal codon 453,
WI-SQ mutation). To generate the double mutant, primers
CVO022 and CVO451 were used, using pBLD413 as template.
The product was cloned into pMAL c2x using EcoRI and
HindIII.
Protein Purification—All proteins were purified from E. coli
strain BL21(DE3) as fusions with maltose-binding protein at
the N terminus and a hexahistidine tag at the C terminus. Pro-
tein production was induced in 1-liter cultures by the addition
of isopropyl -D-1-thiogalactopyranoside to 0.5 mM when the
culture was at an A600 of 0.5. The bacteria were harvested
after an overnight incubation at 18 °C and resuspended in col-
umn buffer (20 mM Tris, pH 7.4, 500 mM NaCl, 20 mM imidaz-
ole) containing protease inhibitors (Complete EDTA-freeMix-
ture, Roche Applied Science). The bacteria were lysed with a
cell disruptor (Constant Cell Disruption Systems), and the
lysate was sonicated with a microtip for three 30-s pulses (50%
duty cycle, setting 4; Vibracell, Sonics and Materials). Lysates
were clarified by centrifugation in a JA25.5 rotor at 9000 g for
30 min. The clarified lysates were mixed with Ni2-nitrilotri-
acetic acid resin (Qiagen) and incubated at 4 °C for 1 h while
rotating. The mixture was poured into a 1.5 12-cm chroma-
tography column (Bio-Rad), and the resinwaswashedwith50
column volumes of column buffer. The protein was eluted with
5 columnvolumes of columnbuffer supplementedwith 250mM
imidazole. The eluate was concentrated to 0.5–1.5 ml using a
Vivaspin 15 concentrator (Sartorium Stedim Biotech) and
loaded onto a HiLoad 26/60 Superdex 200 prep-grade column
equilibrated in standard assay buffer (10 mM HEPES-Na, pH
7.4, 1 mM EDTA, 50 mM NaCl, pH 7.4). Elution of protein was
detected through monitoring the UV absorption of the eluate,
followed by SDS-PAGE. The fractions containing monomeric
protein were concentrated as described above, aliquoted, and
snap-frozen in liquid nitrogen.We were unable to purify unag-
gregated full-length protein containing theTrp-448 and Ile-449
point mutations in five independent attempts; as aggregated
protein is not active, this mutant was not included in the
analysis.
Phospholipid Transfer Assay—Phospholipid transfer activity
was measured as described previously (44). Briefly, donor vesi-
cles and acceptor vesicles were produced by mixing 98 mol %
phosphatidylcholine and 2 mol % phosphatidic acid or 88
mol % phosphatidylcholine, 2 mol % phosphatidic acid, 10
mol % N-lactosyl-phosphatidylethanolamine (all non-radioac-
tive lipids were obtained from Avanti Polar Lipids, Inc.) and a
trace of 14C-labeled phosphatidylcholine (L--dipalmitoyl-
phosphatidylcholine; PerkinElmer Life Sciences), respectively.
To this mixture, 200l chloroformwas added, and themixture
was dried under a stream of N2 gas until completely dry. The
dried lipids were resuspended in standard assay buffer and sol-
ubilized in a sonicatingwater bath (UltrawaveU300H) until the
solution became completely translucent. Tomeasure phospho-
lipid transfer, 69 nmol of acceptor vesicles were mixed with 23
nmol of donor vesicles in the presence of 1 mg/ml essentially
fatty acid-free bovine serum albumin (Sigma), followed by the
addition of protein to a final concentration of 25 g/ml. The
final volume of the reaction was 100l. This mixture was incu-
bated at 37 °C for 30 min. To measure total radioactivity in the
sample, a small aliquot was removed, and radioactivity was
counted using scintillation counting. To the remaining mix-
ture, agglutinin RCA120 (lectin from Ricinus communis; Sigma)
was added to agglutinate the donor vesicles, and the samples
were incubated on ice for 30 min, followed by incubation at
room temperature for 10 min. The agglutinated donor vesicles
were pelleted by centrifugation for 6 min at 13,000 rpm in a
microcentrifuge. The radioactivity in the supernatant was then
measured using scintillation counting, and the amount of trans-
fer was calculated.
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